The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.
暂无分享,去创建一个
Jing Wang | Yimin Qian | George M Burslem | C. Crews | Y. Qian | Ashton C Lai | Daniel P. Bondeson | Saul Jaime-Figueroa | J. Hines | Hanqing Dong | Jing Wang | A. Crew | George M. Burslem | Blake E Smith | S. Jaime-Figueroa | D. McQuaid | M. Toure | Craig M Crews | Momar Toure | Daniel C McQuaid | Daniel P Bondeson | Hanqing Dong | Andrew P Crew | John Hines | Blake E. Smith
[1] Geoffrey R. Oxnard,et al. Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer , 2013, Science Translational Medicine.
[2] A. Scott,et al. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. , 2009, Neoplasia.
[3] N. Iqbal,et al. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications , 2014, Molecular biology international.
[4] Ming-Sound Tsao,et al. An overview of the c-MET signaling pathway , 2011, Therapeutic advances in medical oncology.
[5] D. Stolz,et al. Cross-talk between Epidermal Growth Factor Receptor and c-Met Signal Pathways in Transformed Cells* , 2000, The Journal of Biological Chemistry.
[6] L. Jones,et al. Selective Downregulation of JAK2 and JAK3 by an ATP-Competitive pan-JAK Inhibitor. , 2017, ACS chemical biology.
[7] V. Lang,et al. Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin‐binding entities , 2009, EMBO reports.
[8] T. Heightman,et al. Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras , 2016, ACS central science.
[9] K. Takeuchi,et al. Receptor tyrosine kinases and targeted cancer therapeutics. , 2011, Biological & pharmaceutical bulletin.
[10] Julien Michel,et al. Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction , 2012, Journal of the American Chemical Society.
[11] R. Deshaies,et al. Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[12] M. Naujokas,et al. Met/Hepatocyte Growth Factor Receptor Ubiquitination Suppresses Transformation and Is Required for Hrs Phosphorylation , 2005, Molecular and Cellular Biology.
[13] A. Misra,et al. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. , 2013, Biomaterials.
[14] J. Ovádi,et al. Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals). , 2017, Journal of medicinal chemistry.
[15] J. Baselga,et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] James S. Duncan,et al. Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. , 2016, Cell reports.
[17] L. Neckers,et al. Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors , 2009, Cell cycle.
[18] D. Fenyo,et al. Phosphotyrosine Signaling Networks in Epidermal Growth Factor Receptor Overexpressing Squamous Carcinoma Cells*S , 2005, Molecular & Cellular Proteomics.
[19] C. Crews,et al. Chemical biology: Greasy tags for protein removal , 2012, Nature.
[20] T. Corson,et al. Small-Molecule Hydrophobic Tagging Induced Degradation of HaloTag Fusion Proteins , 2011, Nature Chemical Biology.
[21] T. Pellinen,et al. Small GTPase Rab21 regulates cell adhesion and controls endosomal traffic of β1-integrins , 2006, The Journal of cell biology.
[22] A. Marcus,et al. Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer. , 2001, Human pathology.
[23] Sun-Mi Park,et al. Foretinib (GSK1363089), an Orally Available Multikinase Inhibitor of c-Met and VEGFR-2, Blocks Proliferation, Induces Anoikis, and Impairs Ovarian Cancer Metastasis , 2011, Clinical Cancer Research.
[24] V. Calléja,et al. A direct role for Met endocytosis in tumorigenesis , 2011, Nature Cell Biology.
[25] C. Crews,et al. Development and characterization of proteasome inhibitors. , 2005, Methods in enzymology.
[26] James S. Duncan,et al. Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. , 2015, Cell reports.
[27] W. L. Jorgensen,et al. Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α. , 2012, Angewandte Chemie.
[28] L. Neckers,et al. The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models. , 2013, Cancer research.
[29] A. Ullrich,et al. The discovery of receptor tyrosine kinases: targets for cancer therapy , 2004, Nature Reviews Cancer.
[30] C. Klein,et al. Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker , 2012, Journal of Pharmacology and Experimental Therapeutics.
[31] T. Corson,et al. Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs , 2013, Proceedings of the National Academy of Sciences.
[32] I. E. Smith,et al. HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins. , 2015, ACS chemical biology.
[33] C. Crews,et al. Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. , 2008, Bioorganic & medicinal chemistry letters.
[34] S. Akinaga,et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. , 2009, Blood.
[35] Carmen Birchmeier,et al. Targeting MET in cancer: rationale and progress , 2012, Nature Reviews Cancer.
[36] A. Xu,et al. Receptor tyrosine kinase coactivation networks in cancer. , 2010, Cancer research.
[37] C. Crews,et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. , 2015, Chemistry & biology.
[38] A. Ciulli,et al. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4 , 2015, ACS chemical biology.
[39] Eunhwa Ko,et al. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. , 2016, Angewandte Chemie.
[40] S. Ogawa,et al. Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. , 2010, Biochemical and biophysical research communications.
[41] Adriana L. Gonzalez,et al. Epidermal Growth Factor Receptor (EGFR) Antibody Down-regulates Mutant Receptors and Inhibits Tumors Expressing EGFR Mutations* , 2006, Journal of Biological Chemistry.
[42] H. Band,et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. , 2001, Molecular cell.
[43] Joon-Oh Park,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.
[44] P. Parker,et al. Protein Kinase C Controls Microtubule-based Traffic but Not Proteasomal Degradation of c-Met* , 2003, Journal of Biological Chemistry.
[45] Liu Liu,et al. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression , 2017, Journal of medicinal chemistry.
[46] P. Jänne,et al. Pharmacological Targeting of the Pseudokinase Her3 , 2014, Nature chemical biology.
[47] J. Schlessinger,et al. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[48] D. Lamont,et al. Structural basis of PROTAC cooperative recognition for selective protein degradation , 2017, Nature chemical biology.
[49] A. Drilon. MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life , 2016, Clinical Cancer Research.
[50] C. Crews,et al. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. , 2017, Cell chemical biology.
[51] Amanda Doucette,et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.
[52] Chad J. Miller,et al. A comprehensive mathematical model for three-body binding equilibria. , 2013, Journal of the American Chemical Society.
[53] W. Birchmeier,et al. Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.
[54] A. Bozec,et al. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. , 2007, Critical reviews in oncology/hematology.
[55] M. Wislez,et al. Mutations at the splice sites of exon 14 of MET gene: a new target for sarcomatoid carcinomas? , 2016, Annals of translational medicine.
[56] K. Bhalla,et al. Targeting HSP90 for cancer therapy , 2009, British Journal of Cancer.
[57] James S. Duncan,et al. The dynamic nature of the kinome. , 2013, The Biochemical journal.
[58] C. Crews,et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer , 2016, Proceedings of the National Academy of Sciences.
[59] Somasekar Seshagiri,et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. , 2006, Cancer research.
[60] I. E. Smith,et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. , 2015, Nature chemical biology.
[61] G. Scagliotti,et al. Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] L. Sequist,et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] L. Neckers,et al. Low Dose Geldanamycin Inhibits Hepatocyte Growth Factor- and Hypoxia-Stimulated Invasion of Cancer Cells , 2007, Cell cycle.
[64] M. Berger,et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. , 2006, Cancer research.